Arbutus’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Arbutus is a biopharmaceutical firm that develops therapies for the treatment of hepatitis B virus infection. Read more

Arbutus is a biopharmaceutical firm that develops therapies for the treatment of hepatitis B virus infection. Read more

William H. Collier's photo - President & CEO of Arbutus

President & CEO

William H. Collier

CEO Approval Rating

91/100

Founded:

2005

Status:

PublicNASDAQABUS

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Immune Design is perceived as one of Arbutus's biggest rivals. Immune Design was founded in 2008 in Seattle, Washington. Immune Design is in the Pharmaceuticals field. Immune Design generates $12.9M less revenue than Arbutus.

Dicerna is Arbutus's #2 rival. Dicerna is a Public company that was founded in 2006 in Lexington, Massachusetts. Dicerna competes in the Pharmaceuticals field. Compared to Arbutus, Dicerna has 108 more employees.

Agenus, Inc. is one of Arbutus's top competitors. Agenus, Inc.'s headquarters is in Lexington, Massachusetts, and was founded in 1994. Like Arbutus, Agenus, Inc. also operates in the Biotechnology industry. Agenus, Inc. generates 637% of Arbutus's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Inovio a competitor of Arbutus?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$15.1M

Arbutus's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 86.3M. Over the last three quarters, Arbutus's revenue has decreased by 6.4%. Specifically, in Q2 2020's revenue was $1.5M; in Q1 2020, it was $1.5M; in Q4 2019, it was $1.6M.

Acquisitions

No recent acquisitions found related to Arbutus

Arbutus Funding History

$116M

Since Arbutus was founded in 2005, it has participated in 1 round of funding. In total Arbutus has raised $116.0M. Arbutus' funding round was on Jan 2018 for a total of $116.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jan 2018
$116M

Roivant Sciences Ltd

Since Arbutus was founded in 2005, it has participated in 1 round of funding. In total Arbutus has raised $116.0M. Arbutus' funding round was on Jan 2018 for a total of $116.0M

Investments

No recent investments found related to Arbutus

Arbutus News

September 15, 2020MarketScreener

Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg

(marketscreener.com) Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety and ... See more »
August 7, 2020NewsOk

2Q Earnings Snapshot

WARMINSTER, Pa. (AP) _ Arbutus Biopharma Corp.Read more on NewsOK.com... See more »
August 7, 2020BioSpace

Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with r... See more »

Arbutus Press Releases

July 24, 2020centralcharts

Arbutus Biopharma Corporation - ABUS Stock Chart Technical Analysis for 07-24-2020

News videos - Arbutus Biopharma Corporation - ABUS Stock Chart Technical Analysis for 07-24-2020 - Pu... See more »
May 27, 2020GlobeNewswire

Arbutus to Present at Jefferies Virtual Healthcare Conference

WARMINSTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a cli... See more »
May 18, 2020GlobalNewswire

Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg

Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout ... See more »
May 12, 2020GlobeNewswire

Arbutus to Present at UBS Virtual Global Healthcare Conference

WARMINSTER, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a cli... See more »
February 10, 2020GlobeNewswire

Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer

Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020... See more »
July 23, 2019GlobeNewswire

Veritas Reaches a Mutual Settlement with Arbutus Biopharma Corporation

VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Inc. (CSE: VRT; ... See more »
July 2, 2019GlobeNewswire

Arbutus Sells Part of its ONPATTRO (patisiran) Royalty Interest to OMERS

- Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant d... See more »

Headquarters

701 Veterans Circle

Warminster, Pennsylvania18974

267-469-0914

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Arbutus is a biopharmaceutical firm that develops therapies for the treatment of hepatitis B virus infection. Arbutus was founded in 2005. Arbutus' headquarters is located in Warminster, Pennsylvania, USA 18974. It has raised 116.0M in 1 round. The la...

CEO

Arbutus's President & CEO, William H. Collier, currently has an approval rating of 91%. Arbutus's primary competitors are Immune Design, Dicerna & Agenus, Inc..

Website

arbutusbio.com

Frequently Asked Questions about Arbutus

  1. When was Arbutus founded?

    Arbutus was founded in 2005
  2. Who is Arbutus's CEO?

    Arbutus's CEO is William H. Collier
  3. How much revenue does Arbutus generate?

    Arbutus generates $15.1M in revenue
  4. How much funding does Arbutus have?

    Arbutus has historically raised $116M in funding
  1. Where is Arbutus's headquarters?

    Arbutus's headquarters is in Warminster Pennsylvania, USA
  2. How many employees does Arbutus have?

    Arbutus has 79 employees
  3. What sector does Arbutus operate in?

    Arbutus is in Biotechnology, Pharmaceuticals
  4. Who are Arbutus's competitors?

    Arbutus's top competitors are Immune Design, Dicerna, Agenus, Inc.